• Introduction to Breast Cancer
    • Introduction to Breast Cancer

      Breast cancer is mainly divided into non-invasive and invasive breast cancer, in which invasive breast cancer can be further classified into 4 types: luminal type A, luminal type B, HER2 over expression and Basal-like type according to the expression status of ER, PR, HER2 genes. Different molecular types are treated differently.

      Product Overview:
      Product Features:
      Suitable Patient Profile:
  • Significance of Gene Testing in Breast Cancer
    • Significance of Gene Testing in Breast Cancer

      5%-10% of breast cancers are hereditary. By detecting people at high risk of breast cancer through genetic screening, the incidence of breast cancer can be monitored and prevented in advance, and mortality can thus be reduced.
      The American Society of Breast Surgeons' Consensus Guidelines for Breast Cancer Genetic Testing suggest that all breast cancer patients should be genetically tested. In the course of breast cancer treatment, there is often drug resistance situation. Gene testing can indicate the occurrence of drug resistance and support the rational selection of drugs as well as suggest the use of targeted therapeutic drugs. For some patients who do not want to undergo chemotherapy after surgery, genetic testing can also outline chemotherapy benefits and predict the risk of recurrence.

      Product Overview:
      Product Features:
      Suitable Patient Profile:
  • Genetron in Breast Cancer Testing
    • Genetron’s BRCA1/2 Testing

      In strict accordance with the 'Chinese breast cancer patients BRCA1/2 gene testing and clinical application expert consensus (2018 edition)' Guidance, test area covering the shear sites upstream and downstream 20bp

      Not only can point mutations, insertions, deletions be detected, but also large fragment rearrangements

      Passed the 2018 China Medical Device Industry Association 'NGS BRCA Calibration Program' with full score

      Product Overview:
      Product Features:
      Suitable Patient Profile:
    • Genetron’s Female 20 Genes Testing

      Female 20 genes, all from the NCCN guidelines recommended to detect breast/ovarian cancer susceptibility genes

      Covering all gynecological tumors

      Can detect nearly 10 genetic syndrome-related genes

      Provide risk management recommendations according to the test results

      Product Overview:
      Product Features:
      Suitable Patient Profile:
  • Genetron’s Genomic Testing Service for Breast Cancer
    • Onco PanScan™️ (tissue /blood)

      Product Overview:

      Combined with Genetron’s universal tumor database, the solid tumor 825 genes testing covers an updated version of the WHO, NCCN, ESMO and other authoritative guidelines and expert consensus recommended test genes. Based on the high-throughput, highly sensitive NGS platform and 'hybrid capture' technology, solid tumor 825 genes testing can provide multi-dimensional immunotherapy related biomarker detection (TMB, MSI, PD-L1, immune efficacy related gene variation), so as to guide the individualized diagnosis and treatment of tumor patients more accurately, It also provides more comprehensive reference information for researchers

      Product Features:

      1. Focus on 238 tumor drugs, covering 12 classic tumor signaling pathways, 45 chemotherapy drug related sites, 90 immunotherapy related genes, 149 tumor genetic susceptibility genes
      2. Comprehensive and real-time dynamic monitoring of recurrent metastasis and the mechanism of molecular change in drug-resistant patients, to achieve the full course of cancer monitoring and management
      3. Multi-dimensional immunotherapy assessment

      Suitable Patient Profile:

      Tumor patients seeking more opportunities for targeted drugs or immunotherapy

    • BRCA1/2 Genetic Testing

      Product Overview:

      Based on the one-step technique, all exon regions of the BRCA1/2 genes are detected, as well as the ±20bp of the exon and the introns connection area.
      Provide comprehensive testing of disease-causing sites (point mutations, insertions, deletions and large fragments deletions) for patients

      Product Features:

      1. Integrity of test area : covering the full length of the exon area as well as exon and introns connection area ±20bp; test area is more complete hence ensuring a full complete screening of pathogenic mutation
      2. Accuracy of test results : this does not only detect SNP/InDel, which is highly pathogenic, but also identify large fragment deletions and accurately locate pathogenic mutations.
      3. Strict adherence to guidelines: close monitoring of updates to the guidelines and upgrade the test content based on new information

      Suitable Patient Profile:

      Patients with advanced HER2-negative breast cancer, ovarian cancer patients

    • Female 20 Genes Testing
      Product Overview:

      Based on the second-generation illumina sequencing platform, 20 genes related to female tumor genetics recommended by the NCCN guidelines were selected for professional genetic interpretation to provide accurate services for patients.

      Product Features:

      1. Focus on genes associated with gynecologic cancers: all from the NCCN guidelines, without missing out any possible genes
      2. Strict adherence to guidelines: close monitoring of updates to the guidelines and upgrade the test content based on new information

      Suitable Patient Profile:

      Gynecological tumor patients

  • Assessment Process
    • Assessment Process
      Product Overview:
      Product Features:
      Suitable Patient Profile:
COPYRIGHT © 2020-2023泛生子. ALL RIGHTS RESERVED
Genetron Health Genetron Health Management
COPYRIGHT © 2020-2023泛生子. ALL RIGHTS RESERVED
Messages
  • *To
  • *Subject
  • *Name
  • *Tel
  • Work Unit
  • *Email
  • 详细说明:
  • Check code:
Genetron Health Genetron Health Management